TY - JOUR
T1 - Approaches to Imaging Immune Activation Using PET
AU - Parihar, Ashwin Singh
AU - Pant, Niharika
AU - Heidari, Pedram
AU - Fong, Lawrence
AU - Iravani, Amir
N1 - Publisher Copyright:
COPYRIGHT © 2025 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2025/6/1
Y1 - 2025/6/1
N2 - Learning Objectives: On successful completion of this activity, participants should be able to (1) describe potential atypical response patterns by 18F-FDG following immunotherapeutic strategies; (2) recognize the advantages and limitations of 18F-FDG PET in imaging the immune system in the context of oncology; and (3) describe newer PET radiopharmaceuticals targeting specific cellular or subcellular components of the immune system. Financial Disclosure: Dr. Parihar is supported by the SNMMI Radiopharmaceutical Therapy Research Fellowship and has received financial support from Telix Pharmaceuticals. Dr. Heidari serves as an advisor to Telix Pharmaceuticals and Novartis, has research funding support from Siemens Healthineers and CytoSite Biopharma, and acknowledges federal grant support (K08CA249047). Dr. Fong is a consultant for Abbvie, Innovent, Dendreon, and Roche/Genentech and has received research grants from Abbvie, Merck, and Roche/Genentech. Dr. Iravani has served as an advisor for Novartis, Curium, Lantheus, and Bayer and a consultant for Ambrx through the institution. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CE Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Registry for Radiologic Technologists (ARRT) and Nuclear Medicine Technology Certification Board (NMTCB) to sponsor continuing education for physicians, pharmacists, and nuclear medicine technologists. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive credit—number of credits awarded will be determined by the length of the article. Participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through June 2028. Additional details such as the number of credits issued per article, expiration dates, financial disclosure information, and the process to earn CE credit can also be found in the SNMMI Learning Center.
AB - Learning Objectives: On successful completion of this activity, participants should be able to (1) describe potential atypical response patterns by 18F-FDG following immunotherapeutic strategies; (2) recognize the advantages and limitations of 18F-FDG PET in imaging the immune system in the context of oncology; and (3) describe newer PET radiopharmaceuticals targeting specific cellular or subcellular components of the immune system. Financial Disclosure: Dr. Parihar is supported by the SNMMI Radiopharmaceutical Therapy Research Fellowship and has received financial support from Telix Pharmaceuticals. Dr. Heidari serves as an advisor to Telix Pharmaceuticals and Novartis, has research funding support from Siemens Healthineers and CytoSite Biopharma, and acknowledges federal grant support (K08CA249047). Dr. Fong is a consultant for Abbvie, Innovent, Dendreon, and Roche/Genentech and has received research grants from Abbvie, Merck, and Roche/Genentech. Dr. Iravani has served as an advisor for Novartis, Curium, Lantheus, and Bayer and a consultant for Ambrx through the institution. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CE Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Registry for Radiologic Technologists (ARRT) and Nuclear Medicine Technology Certification Board (NMTCB) to sponsor continuing education for physicians, pharmacists, and nuclear medicine technologists. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive credit—number of credits awarded will be determined by the length of the article. Participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through June 2028. Additional details such as the number of credits issued per article, expiration dates, financial disclosure information, and the process to earn CE credit can also be found in the SNMMI Learning Center.
KW - FDG, PET
KW - immune-related adverse events
KW - immunotherapy
KW - tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=105007298336&partnerID=8YFLogxK
U2 - 10.2967/jnumed.124.268289
DO - 10.2967/jnumed.124.268289
M3 - Review article
C2 - 40306967
AN - SCOPUS:105007298336
SN - 0161-5505
VL - 66
SP - 839
EP - 847
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 6
ER -